ArticleCancer research2020
Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma.
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06865339 (TRIPL), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TRIPL: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
Who cites it
16 citing papers in PubMed.
- The tumor immune microenvironment in primary cutaneous melanoma.Archives of dermatological research · 2025Review
- Spatial Transcriptomics in Inflammatory Skin Diseases Using GeoMx Digital Spatial Profiling: A Practical Guide for Applications in Dermatology.JID innovations : skin science from molecules to population health · 2025Article
- Emerging dimensions of autophagy in melanoma.Autophagy · 2024Review
- Macrophage diversity in human cancers: New insight provided by single-cell resolution and spatial context.Heliyon · 2024Review
- Integrating single-cell and spatial transcriptomic analysis to unveil heterogeneity in high-grade serous ovarian cancer.Frontiers in immunology · 2024Article
- Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.The Journal of pathology · 2023Review
- Spatial Transcriptomics Depict Ligand-Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors.Cancer research · 2023Article
- Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancer.Cancer medicine · 2023Article
- Targeting the immune microenvironment for ovarian cancer therapy.Frontiers in immunology · 2023Review
- An update on methods for detection of prognostic and predictive biomarkers in melanoma.Frontiers in cell and developmental biology · 2023Review
- Red Light Phototherapy Using Light-Emitting Diodes Inhibits Melanoma Proliferation and Alters Tumor Microenvironments.Frontiers in oncology · 2022Article
- Multiparameter persistent homology landscapes identify immune cell spatial patterns in tumors.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Identification of Genes Potentially Associated with Melanoma Tumorigenesis Through Co-Expression Network Analysis.International journal of general medicine · 2021Article
- Data mining of immune-related prognostic genes in metastatic melanoma microenvironment.Bioscience reports · 2020Article
- 20/20 in 2020: seeking clarity on the management of stage III melanoma in a rapidly changing treatment environment.Annals of translational medicine · 2020Article
- Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Patients with resected stage II-III melanoma have approximately a 35% chance of death from their disease. A deeper understanding of the tumor immune microenvironment (TIME) is required to stratify patients and identify factors leading to therapy resistance. We previously identified that the melanoma immune profile (MIP), an IFN-based gene signature, and the ratio of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.